ABC-DLBCL relies heavily on NF-κB signaling and shows chronic BCR activation that is needed for survival, which translates into differential sensitivity to drugs targeting these pathways between ABC and GCB DLBCL cases [21, 22]. The gene discussed is NFKB1; the disease is diffuse large B-cell lymphoma.